These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29381268)

  • 1. New-onset serositis in a kidney transplant patient.
    Bobba S; Fattah H; Massey HD; Gupta G
    Am J Transplant; 2018 Feb; 18(2):518-520. PubMed ID: 29381268
    [No Abstract]   [Full Text] [Related]  

  • 2. Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA.
    Mehta SG; Chang JH; Alhamad T; Bromberg JS; Hiller DJ; Grskovic M; Yee JP; Mannon RB
    Am J Transplant; 2019 May; 19(5):1597-1598. PubMed ID: 30468563
    [No Abstract]   [Full Text] [Related]  

  • 3. Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs.
    Danovitch GM; Bunnapradist S; Cohen D; Hariharan S; McKay D; Ratner L; Stegall MD; Steiner RW; Stock PG; Vincenti F
    Am J Transplant; 2021 Nov; 21(11):3811. PubMed ID: 34080294
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
    Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
    Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
    Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
    Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Ischemic Time, Delayed Graft Function, and Graft and Patient Outcomes in Live Donor Kidney Transplant Recipients.
    Krishnan AR; Wong G; Chapman JR; Coates PT; Russ GR; Pleass H; Russell C; He B; Lim WH
    Am J Transplant; 2016 Sep; 16(9):2714-23. PubMed ID: 27037866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney transplant graft outcomes in 379 257 recipients on 3 continents.
    Merion RM; Goodrich NP; Johnson RJ; McDonald SP; Russ GR; Gillespie BW; Collett D
    Am J Transplant; 2018 Aug; 18(8):1914-1923. PubMed ID: 29573328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell-mediated rejection in kidney transplant recipients: The end(point) is also the beginning.
    Chandran S; Mannon RB
    Am J Transplant; 2022 Mar; 22(3):683-684. PubMed ID: 35073440
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-derived Philadelphia chromosome-positive B cell lymphoblastic leukemia presenting with renal allograft involvement in the first year posttransplant.
    Cassol CA; Hod-Dvorai R; Hubbell C; Aggarwal V; Sinha S; Gentile T; Hutchison RE
    Am J Transplant; 2019 Mar; 19(3):956-957. PubMed ID: 30222902
    [No Abstract]   [Full Text] [Related]  

  • 14. A renal transplant recipient with weakness and dyspnea.
    Ting IW; Yeh HC; Huang JW
    Am J Transplant; 2012 May; 12(5):1347-9. PubMed ID: 22537265
    [No Abstract]   [Full Text] [Related]  

  • 15. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function.
    Ravindra KV; Sanoff S; Vikraman D; Zaaroura A; Nanavati A; Sudan D; Irish W
    Am J Transplant; 2019 Mar; 19(3):781-789. PubMed ID: 30171800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and prognosis of late acute rejection in Chinese kidney transplant recipients.
    Mok MMY; Ma MKM; Yap DYH; Chan GSW; Lam MF; Kwok JSY; Kwan LPY; Chan GCW; Choy CBY; Tang SCW; Chan TM
    Nephrology (Carlton); 2017 Dec; 22(12):985-992. PubMed ID: 27587222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.